Concepedia

Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib

Taiga Otsuka, Yuichiro Eguchi, Seiji Kawazoe, Kimihiko Yanagita, Keisuke Ario, Kenji Kitahara, Hiroaki Kawasoe, Hiroyuki Kato, Toshihiko Mizuta

Hepatology Research · 2012 · 96 citations · 23 references

DOIFull text

Open access

Abstract

Skin toxicities occur commonly at the early phase in patients treated with sorafenib, and could be a promising surrogate marker for the treatment outcome.

References

23

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 12.8K citations · Full text

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +12

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text